Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort

Key Points

• To determine the optimal initial relative dose intensity of modified FOLFIRINOX for treating pancreatic ductal adenocarcinoma.
• Conducted a retrospective multi-center cohort study
• Analyzed treatment data of Taiwanese PDAC patients
• Assessed efficacy and tolerability associated with various initial dose intensities.
• An initial relative dose intensity of 70-90% for irinotecan and oxaliplatin was optimal.
• Patients experienced improved efficacy and tolerability at this dose range.

Abstract